title: Effects of two weeks of topical budesonide treatment on microvascular exudative responsiveness in healthy human nasal airways.
abstract: Extravasation and luminal entry of plasma (mucosal exudation) is not only a key feature of airway inflammation in rhinitis and asthma but also a major first-line respiratory defence mechanism. Topical steroids are effective antiexudative agents in disease but, so far, little is known about the direct effects of these drugs on the responsiveness of the microcirculation in human airways. In this study, the effects of prolonged budesonide treatment on histamine-induced mucosal exudation of plasma was examined in 42 healthy subjects. Placebo and budesonide (100 microg per nasal cavity b.i.d.) were given for 2 weeks in a double-blind and placebo-controlled parallel-group protocol. Using a nasal pool technique, nasal challenges with isotonic saline and histamine (40 and 400 microg x mL(-1)) were carried out before and late in the treatment periods. The lavage fluid levels of alpha2-macroglobulin were measured as an index of mucosal exudation of bulk plasma. Histamine produced concentration-dependent mucosal exudation of plasma before as well as after treatment with either placebo or budesonide. The topical steroid treatment only marginally (1.8 fold) decreased the response to the low concentration histamine (40 microg x mL(-1)) and, although it was significantly (2.8 fold) reduced, histamine 400 microg x mL(-1) still produced significant mucosal exudation of plasma in the budesonide group. If the present observations are extrapolated to inflammatory conditions, the antiexudative effects of topical steroids in rhinitis (and asthma) may reflect only a small degree of microvascular antipermeability effects. We suggest that topical steroid treatment may not impede mucosal exudation responses when called for in acute human airway defence reactions.
authors.affiliation: Dept of Otorhinolaryngology, Head and Neck Surgery, Lund University Hospital, Sweden.
authors.forename: L
authors.initials: L
authors.lastname: Greiff
authors.forename: M
authors.initials: M
authors.lastname: Andersson
authors.forename: C
authors.initials: C
authors.lastname: Svensson
authors.forename: A
authors.initials: A
authors.lastname: Akerlund
authors.forename: U
authors.initials: U
authors.lastname: Alkner
authors.forename: C G
authors.initials: CG
authors.lastname: Persson
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D019819:Budesonide; D004311:Double-Blind Method; D005122:Exudates and Transudates / Q000187:drug effects*; D005938:Glucocorticoids; D006632:Histamine / Q000008:administration & dosage; D006801:Humans; D017817:Nasal Lavage Fluid / Q000737:chemistry; D009297:Nasal Mucosa / Q000187:drug effects* / Q000378:metabolism; D011282:Pregnenediones / Q000008:administration & dosage*; D012016:Reference Values; D000511:alpha-Macroglobulins / Q000032:analysis / Q000187:drug effects*
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011282:Pregnenediones; D000511:alpha-Macroglobulins; D019819:Budesonide; D006632:Histamine